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Microglia are the innate immune cells of the CNS with an embryonic origin and self-renew 
with a slow turnover throughout life. The health-promoting capacities of this cell are being 
acknowledged through updated and specific tools separating microglia from bone 
marrow-derived macrophages. Knowing that microglia depends on TGF-β signaling in 
acquiring a mature homeostatic phenotype, we also found this cytokine to mediate the 
integration of monocyte-derived cells into an empty myeloid CNS niche. Microglia or the 
integrated monocyte-derived macrophages, absent in TGF-β signaling, developed a 
damaging phenotype causing spontaneous de-myelination, clinical motor deficits, and 
death of experimental mice.  
Multiple sclerosis (MS) is a de-myelinating autoimmune CNS disease, commonly with 
onset in young adults as a relapsing-remitting disease that over time converts to a 
progressive accumulation of clinical deficits. The etiology of MS is partly inherited but, in 
many aspects, unknown, although we have successful treatments targeting the adaptive 
immune system reducing relapses and likely delay progression. However, the progressive 
MS disease, believed to emanate from the cells residing in the CNS, is very limited in 
treatment options. Genetic association studies imply that the microglial cell harness a 
substantial part of the MS-pathogenicity. How this relates to disease phenotypes offering 
treatment targets is sparsely explored.  As the human CNS is rather inaccessible, the use of 
the rodent animal model experimental autoimmune encephalomyelitis (EAE) has been 
instrumental in deciphering the MS pathology. In the recovery phase of this disease, the 
microglial clearance of myelin is of substantial importance. We found this process to 
depend on a lysosomal degradation process referred to as autophagy- or LC3- associated 
phagocytosis. During EAE, microglia lacking the autophagy gene Atg7 accumulated myelin 
debris and had reduced recirculation of scavenger receptors, causing a secondary 
impairment in tissue myelin-clearance.  These cells also acquired an altered transcriptome 
associated with inflammatory microglia/macrophage phenotypes found in, e.g., MS, 
neurodegenerative disease, and stroke, while the genes of the homeostatic signature 
were downregulated. Autophagy is known to alter with age, and we targeted this by 
increasing autophagy-associated phagocytosis in aged microglia by treatment with the 
sugar molecule trehalose, which ameliorated EAE. Of note, trehalose metabolism and 
some autophagy-associated phagocytosis pathway components are associated with MS 
through risk allele analysis.  
Microglial proliferation and survival rely on CSF-1 (M-CSF) or IL-34 mediated 
activation of the CSF-1 receptor (CSF1R). While microglial CSF-1 expression is elevated 
during inflammation, CSF1R associate with the homeostatic microglia.  In the healthy CNS, 
neurons are the main source of IL-34, but a specific role of this cytokine in 
neuroinflammation remains to be evaluated.  The ageing CNS is challenging for microglia 
in terms of adaptations to aid in health-promoting capacities in functions that, together 
with CSF1R signaling, engage canonical-autophagy. This degradation pathway controls the 
quality and quantity of, e.g., inflammatory mediators, receptors, and organelles. By 
deleting the key canonical-autophagy gene Ulk1, we found an age-associated 
subpopulation of microglia with highly activated ERK1/2 upon CSF1R engagement to be 
diminished, a loss not compensated by other microglia or myeloid cells. The loss of this 
population in aged mice caused neural and glial cell death and high mortality in EAE. In 
autophagy-competent aged mice, we could expand this CNS protective population 
specifically by IL-34 treatment and thereby ameliorate disease.     
In this thesis, I present TGF-β as an essential factor in establishing a homeostatic CNS 
myeloid cell and a demand in aged microglia for canonical-autophagy to maintain a 
neuroprotective phenotype. The myelin processing by microglia through autophagy-
associated phagocytosis is dissected in detail, and we can show how a decline in this 




LIST OF SCIENTIFIC PAPERS 
 
I.  Berglund R, Guerreiro-Cacais AO, Adzemovic MZ, Zeitelhofer M, Lund H, 
Ewing E, Ruhrmann S, Nutma E, Parsa R, Thessen-Hedreul M, Amor S, 
Harris RA, Olsson T, Jagodic M.  
Microglial autophagy-associated phagocytosis is essential for recovery from 
neuroinflammation. Science Immunology, 5., 52 (2020) 
 
II.  Berglund R, Guerreiro-Cacais AO, Piket E, Jagodic M, Olsson T.  
The ageing CNS is protected from neuroinflammation by an autophagy 
dependent microglia population promoted by IL-34. Manuscript 
 
III. Lund H, Pieber M*, Parsa R*, Grommisch D, Ewing E, Kular L, Han J, Zhu 
K, Nijssen J, Hedlund E, Needhamsen M, Ruhrmann S, Guerreiro-Cacais AO, 
Berglund R, Forteza MJ, Ketelhuth DFJ, Butowsky O, Jagodic M, Zhang 
XM*, Harris RA*.   
Fatal de-myelinating disease is induced by monocyte derived macrophages in 
the absence of TGF-β signaling. Nature Immunology. 19(5), 1-7 (2018). 


























SCIENTIFIC PAPERS NOT INCLUDED IN THE THESIS 
 
I.  Hochmeister S, Aeinehband S, Dorris C, Berglund R, Haindl MT, Velikic V, 
Gustafsson SA, Olsson T, Piehl F, Jagodic M, Zeitelhofer M, Adzemovic MZ.   
Effect of Vitamin D on Experimental Autoimmune Neuroinflammation Is Dependent 
on Haplotypes Comprising Naturally Occurring Allelic Variants of CIITA (Mhc2ta). 
Frontiers in Neurology. 13;11 (2020).   
 
II.  Castelo-Branco G, Stridh P, Guerreiro-Cacais AO, Adzemovic MZ, Falcão AM, 
Marta M, Berglund R, Gillett A, Hamza KH, Lassmann H, Hermanson O, Jagodic 
M.  
Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of 
experimental autoimmune encephalomyelitis and prevents brain pathology in DA 
rats. Neurobiology of Disease. 71:220-33 (2014).  
 
III.  Guerreiro-Cacais AO, Norin U, Gyllenberg A, Berglund R, Beyeen A D, 
Rheumatoid Arthritis Consortium International (RACI), Petit-Teixeira E, Cornélis F, 
Saoudi A, Fournié G J, Holmdahl R, Alfredsson L, Klareskog L, Jagodic M, Olsson 
T, Kockum I & Padyukov L.   
VAV1 regulates experimental autoimmune arthritis and is associated with anti-CCP 




1. INTRODUCTION    
 1.1  Multiple sclerosis         1 
 1.2  Rodent models of multiple sclerosis     3 
 1.3  Microglial origin and kinetics       3 
 1.4  Models of microglial depletion      4 
 1.5  Microglial phenotypes        5 
  1.5.1 Homeostatic microglia and tissue interactions  5 
  1.5.2 TGF-β           5 
  1.5.3 Microglial phenotypes in CNS pathology   5 
  1.5.4 Phagocytosis and re-myelination in MS and EAE  6 
  1.5.5 The receptors regulating and executing microglial 6  
  1.5.6 APOE and CLEC7A       7 
  1.5.7 Microglia in neurogenesis and microglial   7 
     neurotrophic features  
  1.5.8 Damaging and pathogenic microglial processes 8 
 1.6  Ageing microglia         9 
 1.7  Infiltrating and border-associated-myeloid cells   9 
 1.8  Autophagy           10 
  1.8.1  Canonical-autophagy       10 
  1.8.2  Non-canonical autophagy and phagocytosis  11 
  1.8.3  Autophagy in the pathology MS and     
    other human diseases       12 
  1.8.4  Autophagy as a pharmaceutical target   13
 
2. METHODOLOGICAL CONSIDERATIONS 
 2.1  Mouse Cre-Lox models        14 
 2.2  The Diphtheria-toxin mediated depletion of microglia 14  
 2.3  The EAE model          15 
 2.4  Microglial phenotyping in vivo and in vitro    15 
 2.5 Autophagy monitoring and phagocytosis assays   15 
 2.6  Analysis of RNA sequencing data      16 
3. ETHICAL CONSIDERATIONS       16 
4. AIMS             16 
5. RESULTS            17 
 5.1 Paper I            17 
 5.2 Paper II            19 
 5.3 Paper III            20 
6. DISCUSSION AND FUTURE PERSPECTIVES    22 
7. ACKNOWLEDGEMENTS         25 














ALS Amyotrophic lateral sclerosis 
AMPK 5' adenosine monophosphate-activated protein kinase 
ATG Autophagy related gene/protein 
BAM Border-associated macrophages 
BBB Blood-Brain-Barrier 
BMDM Bone-marrow derived myeloid cell/macrophage 
CD Cluster of differentiation 
CLEC C-type lectin 
CNS  Central nervous system 
CSF Colony stimulating factor 
CX3CR1 Chemokine(C-X-C motif) 3 receptor 1 
DAM Disease-associated microglia 
DCs Dendritic cells 
EAE Experimental autoimmune encephalomyelitis  
ERK Extracellular signal-regulated kinases 
IL Interleukin 
LC3 Microtubule-associated proteins 1A/1B light chain 3 
MOG Myelin Oligodendrocyte Glycoprotein 
MS Multiple sclerosis 
MSR1 Macrophage Scavenger Receptor 1 
mTOR mechanistic target of rapamycin 
OPC Oligodendrocyte progenitor cell 
PLP Proteolipid protein 
PPMS Primary progressive MS 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
RRMS Relapsing-remitting MS 
SLE Systemic lupus erythematosus 
SPMS Secondary progressive MS 
TAM Tamoxifen 
TGF-β Transforming growth factor beta 
TH T-helper cell 
TNF  Tumor necrosis factor  
TREM2 Triggering receptor expressed on myeloid cells 2 





1.1 MULTIPLE SCLEROSIS  
Multiple sclerosis (MS) is a leading cause of neurological disability of young adults, with 
close to three million cases worldwide and a high and increasing prevalence in northern 
Europe and the US of about 1 per 750 citizens 1,2. In MS, an aberrant immune activation 
towards myelin and neuronal epitopes cause de-myelination and axonal damage leading to 
neurological deficits determined by the localization of the inflammatory lesion3. The 
variety of signs and symptoms include motor deficits, sensory losses, and cognitive 
impairment. They commonly appear in the age 20-40 as a Relapsing-Remitting MS 
(RRMS) in which a recovery phase follows clinical manifestations. In many patients, the 
recovery declines with age, and the symptoms get chronic as the de-myelinated lesions 
expand and neuronal/axonal damage accumulate, resulting in Secondary Progressive MS 
(SPMS). In a small proportion of patients, the recovery is absent already from the onset in a  
Primary Progressive MS (PPMS)3. Charcot first described MS in 1868 as a pathological 
entity. This was followed by a century of observations before the understanding and 
treatments of the disease advanced by genetic association studies, animal models, and the 
development of immune-modulating drugs. The more than 200 genes affecting MS 
susceptibility are predominantly associated with immunity, and many MS genes are highly 
expressed in the CNS resident microglial cell with a phenotype shared to a high degree 
between MS and other neurodegenerative pathologies4. Although the overlap of 
susceptibility risk genes to primary neurodegenerative diseases is small, the MS pathology 
includes neurodegeneration associated with oxidative stress, mitochondrial dysfunction, 
and elevated ion-channel activity5. Similar to primary neurodegenerative diseases where 
e.g., α -synuclein and amyloid-beta is fundamental in pathology, the protein Bassoon is 
recently shown to aggregate in neurons in MS, a pathology found treatable in experimental 
models6. Further, several neurotrophic pathways in myeloid-neuronal interactions, 
including IGF-1-and CD200R signaling, are highlighted pathways in analysis of MS risk 
genes7. In addition to the inherited genetic risk alleles, female gender, smoking, Vitamin D 
deficiency, obesity, and Epstein-Barr virus infection are known factors increasing MS 
incidence, while ageing is the strongest risk factor for disease-progression8.    
 The inflammatory MS-relapses' initiating events are likely varied, but the bouts are 
largely dependent on T-and B-cells specific for CNS-antigens3,9. These cells evade 
tolerance and act synergistically in secondary lymphoid tissues to shape pathogenic TH1 
and TH17 cells with CNS-migratory potential9,10. A break-down of the blood-brain-barrier 
integrity is an early event in MS relapses and a prerequisite for infiltrating pathogenic 
peripheral immune cells, including inflammatory monocytes and adaptive immune cells.  
This is proposed to be an effect derived from CNS resident cells producing e.g., IL-1β and 
IL-6 and direct leucocyte mediated injury3. Today, the inflammatory MS bouts are 
successfully treated by lymphocyte depletion through monoclonal anti-CD20 or anti-CD52 
or by obstructed migration to the CNS by VLA-4 or Sphingosine-1 receptor 
internalization3. These treatments reduce the annual relapse-rate from approximately  0.60 
to 0.1511,12. However, the MS pathology involves other immune and glial cells and the MS 
lesions are, besides from CD8+ T-cells, dominated by macrophages of microglial or 
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monocyte origin13. The vast inflammation in MS is mirrored by elevated levels of pro-
inflammatory cytokines, e.g., IFN-γ, IL-1β, GM-CSF, IL-17, IL-23, TNF, and CXCL-
1314,15. Abrogating treatments or gene ablation in animal models targeting each of these 
cytokines ameliorate disease, but single targeting has not shown to be sufficient to treat 
human MS16-27. In the progressive stages of MS, the BBB is usually more intact, and 
infiltration of peripheral immune cells causing relapses is rare, while other pathogenic 
mechanisms such as dysregulated mitochondria and iron-metabolism appear as stronger 
factors3,28. Treatments targeting infiltrating lymphocytes have a limited effect at this disease 
stage, but CD20+ B-cells, plasma cells, and CD8+ T-cells remain in the CNS and reside in 
meninges, causing subpial cortical inflammation in interplay with parenchymal glial cells29-
31. MS-lesions are characterized by the activation state of macrophages and degree of de-
myelination, which is prominent in both acute relapse and progressive disease32. Innate 
immunity and target tissue interactions in general and specifically microglial phenotypes 
are highlighted in analyses of MS risk genes and progressive disease pathology7,33.  The 
microglial cell acts as a glial cell with neurotrophic support and as an immune cell with 
phenotypes associated with the initial events of MS lesions as well as progressive MS7,13. 
This thesis aims to deconvolute and target pathological mechanisms derived from myeloid 
and microglial dysfunctions. Targeting these cells can potentially abate acute inflammation, 
but the urgent hopes lie in stimulating recovery, re-myelination, and limit axonal damage in 
progressive disease7,13,34,35.            
   Multiple sclerosis 
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1.2 RODENT MODELS OF MULTIPLE SCLEROSIS 
Since its development by Rivers et al. in the 1930s, the experimental autoimmune 
encephalomyelitis (EAE) models of MS have been widely used and central in 
understanding autoimmune de-myelinating inflammation36,37. Most of the T-cell-driven 
pathology and pathognomonic de-myelinating processes with associated axonal damage 
found in human MS have been mimicked by studies in these models36,38. The rodent EAE 
model is induced either by passive immunization in cell-transfer settings or/and by active 
immunization with myelin antigens or emulsified spinal cord. The myelin antigens used are 
complete proteins or peptides with known T- or B-cell immunoreactivity, e.g., MOG. The 
animal species, strains, and antigens offer a wide variety of clinical courses and reproduce 
specific aspects of MS pathology. In passive EAE, induction by transfer of CD4+ T-cells is 
most established, while CD8+ cells are abundant in lesions of both MS and some EAE 
models and shown to either ameliorate or aggravate disease39-42. B-cells cannot transmit 
passive EAE, but depletion in the C57B/6 mouse MOG 1-125aa model ameliorate disease. 
The effect on MOG 35-55 peptide induced disease in the same strain is rather aggravating 
EAE, illustrating that variations in the model can reflect different aspects of human MS43,44. 
Independently of the chosen model, the quantified clinical symptoms are usually an 
ascending paralysis. Besides the triggered adaptive immune response, the innate immune 
cells, including microglia, DCs, and monocyte-derived cells, are all fundamental in the 
EAE pathology, and as the focus of this thesis reviewed in depth below33.  
MS-like disease can also be induced using Theiler or murine corona viruses38,45. To 
specifically study de- and re-myelination, the Cuprizone and the lysolecithin models are 
widely used where chemical damage of myelin is the initial event46. In contrast to EAE, 
these models are not commonly used for the quantification of clinical motor deficits. In the 
studies conducted within this thesis, we employ MOG-induced EAE in C57B/6 mice. 
 
1.3 MICROGLIAL ORIGIN AND KINETICS  
The microglial cell lineage constitutes about 10% of the CNS cells and is defined by 
localization, function, appearance, and recently by its yolk-sac derived ectodermal origin 
and transcriptional profile34,47,48.  Microglia are commonly considered self-renewing with 
an annual turnover in the human CNS of about 28% with less than 1% being positive for 
mitotic labeling in mice and human47-52. The establishment and maintenance of the 
microglia population are dependent on the transcription factors IRF8 and PU.1 and the 
activity of CSF1R53,54.  Accordingly, inactivating mutations of this receptor entail a loss of 
the microglial population in both humans and animal models49,54,55. The CSF1R binds two 
known ligands; CSF-1, expressed primarily by immune cells including microglia, and IL-
34, expressed by neurons and glial cells with ~ 300 times higher concentrations compared 
to CSF-1 during homeostatic CNS conditions56-58. IL-34 has two other known receptors 
expressed at low levels by microglia; Syndecan-1 (CD138) and PTP‐ζ (PTPRZ1). The latter 
suggested to be associated with a neurotrophic phenotype, but neither have a known impact 
on microglial survival nor proliferation59-62. Experimental deletion of IL-34 or CSF-1 genes 
reduces the population in a region-dependent manner while deleting both genes decreases 
microglial counts similar to the low density found in mice carrying CSF1R null 
mutations49,63-65. The downstream effects of the CSF1R engagement are complex with the 
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regulatory activity of several pathways, including NF-κB, ERK, and autophagy steering 
Akt and AMPK66,67.  
Moreover, to maintain the population, microglia are shown to undergo local 
stochastic expansion from differentiated cells both in health and disease, and the support for 
a microglial “stem-cell”, distant CNS-migration, or contribution to the population from 
bone-marrow-derived cells have little support68-70.  
The local renewal of microglia and shaping signals from surrounding tissue gives a 
cue for spatially defined microglia. IL-34 is associated with the forebrain, hippocampal, and 
cortical microglia populations, while CSF-1 is necessary for the neurotrophic microglia 
population in the cerebellum and brainstem63,64,71.  Microglia density is higher in the IL-34 
dependent regions, while microglia in CSF-1 dependent regions are more phagocytic72,73. 
Further, neutralizing anti-CSF-1 antibodies selectively reduces the microglia population in 
white matter CNS, while anti-IL-34 act stronger on the gray matter population56. These 
regional and possibly functionally altered microglia populations derived from IL-34 or 
CSF-1 is possibly attributed to variations in CSF1R affinity and binding kinetics63,74,75. IL-
34 and CSF-1 treatments both ameliorate EAE in a similar fashion, although a moderate but 
evident cytokine-specific microglial polarizing potential is reported57,58,75,76.  
Repopulating microglia post depletion restore the majority of the expression profile 
while bone marrow-derived monocytes populating the microglial niche adopt a “semi-
microglia” transcriptome supporting a tissue-determined homing cue for a microglial 
phenotype in addition to the impact from origin77-80.    
  
1.4 MODELS OF MICROGLIAL DEPLETION  
Attempts to deplete microglia and macrophages have a long history for both scientific and 
therapeutic purposes. In addition to the developmental microglial loss seen in CSF1R/CSF-
1/IL-34 deficient mice, microglia can also be successfully depleted using CSF1R/CSF-1/IL-
34 inhibitors, clodronate liposomes, or Diphtheria toxin/-receptor or Herpes simplex 
receptor transgenic approaches81.  If the depleting condition is released, e.g., withdrawn 
CSF1R inhibition or loss of induced Diphtheria toxin expression, the microglial myeloid 
CNS niece is rapidly reconstituted78,80,82. This restored population's origin is a mixture of 
infiltrating bone marrow-derived myeloid cells and expansion of the microglia that evaded 
depletion78,80. Another strategy described but rather unexplored is a transfer of cytotoxic 
CD8+ T-cells reactive to the GFP expressed in CX3CR1-GFP mice, causing an almost 
complete microglial depletion83.   
Up to date, there is no post-developmental microglia-specific depletion since the 
strategies presented above target bone marrow-derived macrophages and are further 
complicated by a “cytokine storm” and infiltration of peripheral immune cells following 
depletion84,85.  The clinical outcome upon microglial depletion in neuroinflammatory and 
neurodegenerative disease models is mixed which likely reflects the unsolved 






1.5 MICROGLIAL PHENOTYPES  
1.5.1 Homeostatic microglia and tissue interactions  
In healthy conditions, the homeostatic microglia act as a glial cell with trophic neuronal 
support interacting with astrocytes and cells of the oligodendrocyte lineage, and in the 
clearance of tissue debris important in keeping inflammatory processes in check93. The 
homeostatic microglia are characterized in mice by expression of, e.g., P2ry12, Cx3cr1, 
Sall1, and Tmem11972,94. The human microglia is more diverse, but the homeostatic 
population defined by the signature expression of P2RY12, TMEM119, and CX3CR1 is 
found both by single-cell RNA sequencing and mass cytometry72,95,96. In addition to the 
homeostatic core, microglia are further transcriptionally determined by the localization and 
tissue conditions such as age72,95-97. 
 
1.5.2 TGF-β  
The cytokine TGF-β1 (Hereafter referred to as TGF-β) and its signaling through the 
TGFΒR (composed of the TGFBR1 and 2 subunits) is essential in acquiring a microglial 
phenotype and the homeostatic transcriptome98,99.  The TGF-β derived signature is among 
CNS myeloid cells specific for microglia,  and congenital ablation of Tgf-β entails a loss of 
this CNS parenchymal myeloid population100. TGF-β loss does not impair cell survival in 
mature microglia but alters the activation to a pro-inflammatory phenotype98,99.  In 
neuroinflammation, TGF-β acts in dampening inflammation and promoting re-myelination 
by stimulating myelin phagocytosis in EAE98,101-103. Further, TGF-β is shown to stimulate 
myelin phagocytosis by human macrophages in vitro102. TGFΒR2 deletion causes, besides 
the diminished homeostatic microglial phenotype, an activating phosphorylation of 
transcription factor TAK1 regulating microglial derived inflammation99,104.  
 Thus, it is evident how TGF-β has a considerable health-promoting potential to be 
further explored in experimental and human diseases.    
 
1.5.3 Microglial phenotypes in CNS pathology  
Upon challenges such as neuroinflammation and neurodegeneration, the genes defining the 
homeostatic microglia are downregulated, and an activated phenotype collectively referred 
to as Disease-associated microglia (DAM) is acquired4. These phenotypes are characterized 
by a changed transcriptome association with various CNS disorders and models, including 
MS, ALS, and other neurodegenerative conditions4,72,94,105. There is no unified subset of 
“DAM core-genes”, but in many models, these transcriptomes are dependent on TREM2 
signaling4,72,94,105.   
Studies of EAE and experimental neurodegeneration define DAM populations 
enriched for, e.g., Ly86, Clec7A, Apoe, Ccl-2, and Lyz2 accompanied by reduced expression 
of homeostatic genes such as P2ry12 and Tmem11994,105,106. In MS, several DAM 
populations are identified, including a phagocytic population with an enriched expression 
of lysosomal component Lamp1 and suggested to be key in re-myelination72,107. Microglia 
found in human active MS lesions are commonly positive for macrophage markers such as 
p22phox, CD68, CD86, MHC class II molecules, and intracellular myelin, while anti-
inflammatory markers such as CD206 and CD163 are prominent on microglia associated to 
inactive lesions13,103 108. These markers are lost on Tmem119+ microglia from the chronic 
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lesion associated with progressive MS 13,108,109.  Recent findings show active de-myelinated 
lesions microglia to stain for MERTK, TIM-3, and LAMP1, with regulatory and functional 
implications in phagocytosis108. The DAM phenotypes associated with diseases are 
composed of many microglial transcriptional cues for functions that remain to be explored.  
  
1.5.4 Phagocytosis and re-myelination in MS and EAE  
Microglia are CNS resident macrophages, and phagocytosis is a key feature of both DAM 
and homeostatic phenotypes. Phagocytosis is the endocytic process where extracellular 
content is engulfed by receptor-mediated budding of the plasma membrane and degraded 
after fusion with a lysosome. The term macrophage describes an innate immune cell's 
phenotype specialized in phagocytosis but does not state their ontogeny. In MS and EAE, 
microglia are the paramount phagocyte of apoptotic cells and myelin debris generated by 
inflammation, while the damaging de-myelination is executed to a larger extent by 
monocyte-derived macrophages (also referred to as BMDM)101,110-115. Clinical deficits in 
MS and EAE correlate to de-myelination of the axons, and re-myelination both protect the 
axons from further damage and restore the signal transduction, thus recovering 
function116,117. The re-myelination sheets are traceable as they are shorter and thinner, but 
the dynamics of the opposing de- and re-myelination are challenging to study in human 
disease116,117.   
In the de-myelinating cuprizone and corona-virus MS-models and in EAE, re-
myelination depends on the microglial clearance of tissue myelin debris, allowing 
differentiation of Oligodendrocyte-progenitor-cells (OPCs) into myelinating 
Oligodendrocytes (OLs)87,113,118,119.   
 
1.5.5 The receptors regulating and executing microglial 
phagocytosis 
Most significant in dictating the phagocytic microglial phenotype in models of MS, 
Alzheimer´s, and Parkinson´s is the TREM2 receptor94,105,111,120-122. In EAE, gene ablation 
or antibody-mediated blockade of TREM2 aggravates EAE while stimulation with an 
agonistic antibody increases myelin clearance and hence, OPC differentiation and re-
myelination111,123-125. In humans, mutations in the TREM2 gene cause microglial 
dysfunction and the neurodegenerative Nasu-Hakola disease126,127. TREM2 recognizes 
phosphatidylserines. These lipids are found abundantly in myelin, and apoptotic cell 
membranes, and binding not only increases uptake but also stimulates the degradation of 
phagocytosed content126,128-131.  Degradation of debris and apoptotic cells is further shown 
to be regulated by the TAM receptors  - MerTK enriched in the homeostatic TGF-β 
dependent microglia population, and Axl enriched in DAM72,94,105,132,133. The uptake of 
myelin is executed by scavenger receptors MSR1 (SR-A), CR3, CD36, and possibly by 
TREM2 directly128,131,134,135.  
The myelin phagocytosis is not only an executive function of the health-promoting 
microglia. It is also evident how accomplished ingestion and myelin degradation further 
induce a beneficial microglial phenotype in MS and EAE. This phenotype is defined by 
transcriptome analysis and immunohistochemistry defined qualities, including secretion of 
TGF-β and IGF-1, a mediator central in OPC differentiation to myelinating OLs101,136,137.  
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1.5.6 APOE and CLEC7A  
Microglia exposed to apoptotic cells upregulates Apoe and Clec7a (Dectin-1) genes in 
transitioning from a homeostatic to a phagocytic DAM phenotype94. APOE serves as a 
transporter of lipids and as a ligand for intracellular receptors such as the LXR131.  This 
intracellular receptor and transcription factor mediate lipid efflux and initiate lipid 
degradation through increased expression of Apoe in a positive feed-back loop131,138,139. The 
APOE gene contains the strongest risk allele for Alzheimer´s disease and is, through 
binding TREM2, essential for DAM differentiation94,140. The risk-variant APOEe4 
associates with dysregulated phagocytosis, exemplifying an errant DAM phenotype driving 
pathogenesis140-142. Carrying the APOE4 risk allele does not associate with MS 
susceptibility but is suggested to accelerate disease progression143-145.     
 As part of a microglial phenotype enriched for genes promoting phagocytosis and 
phagosome degradation, Clec7a  associates with microglia important in mouse and human 
development146,147. This microglial population is absent in the adult CNS at homeostatic 
conditions but shows similarities to the TREM2-dependent DAM microglia94,105,146,147. The 
CLEC7A is commonly known to bind fungal cell wall compounds but can bind apoptotic 
cells during inflammatory conditions148.  Ablation of the Clec7a gene is suggested to 
aggravate EAE, and activation of CLEC7A by the β-glucan Zymosan promotes axonal 
regeneration through an ERK1/2 pathway149-151.   
 
1.5.7 Microglia in neurogenesis and microglial neurotrophic features  
Microglial phagocytosis is not only a fundamental health-promoting process in the CNS 
during inflammation. From embryogenesis, during development, and in the adult CNS, 
these cells phagocytose apoptotic neural lineage cells and synapses in a process supportive 
of neurogenesis, myelination, and synaptic plasticity152-155. This process relies on the 
microglia population sustained by CSF1R activity and expression of the fractalkine receptor 
(CX3CR1), key in microglial motility and spatial orientation mediated by neuronal 
CX3CL1154,156. The synaptic pruning in neuronal plasticity is shown dependent on 
activation through CR3 and TREM2157,158. On the negative side, in the aged CNS, 
excessive synaptic clearance by complement receptor-activated microglia associate with 
cognitive decline159,160. Neuronal-microglial interaction through CD200-CD200R stabilize 
microglia and possibly act trophic on neurons161. Dysregulation in this and the CX3CL1-
CX3CR1 communication is found in MS lesions, Alzheimer´s disease  and in the ageing 
brain161,162. Disruption of the CX3CR1 signaling also attenuates experimental 
neuroinflammation, although this effect is not defined as specifically microglia 
derived163,164.              
 Pathway analysis of the risk-genes associated with MS highlights the IGF-1, CNTF, 
BDNF, EGF, IL-10, and NGF neurotrophic pathways, all mediators secreted by microglial 
cells during inflammation7.  Of certain interest is Igf1 found enriched in DAM, especially in 
the phagocytic microglia population associated with EAE recovery, the anti-inflammatory 
cytokine IL-10 secreted upon phagocytosis, and BDNF with a known age-associated 
decline101,105,165-167. Microglia is in addition to this neurotrophic support shown to recruit 
neuronal progenitors in the adult CNS in response to tissue damage168.  
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1.5.8 Damaging and pathogenic microglial processes  
Microglia exhibits damaging potential through cytokine and ROS/RNS secretion during 
inflammation or neurodegeneration, and microglial depletion can ameliorate pathology90,91. 
During neuroinflammation, ROS is generated in myeloid cells by myeloperoxidases, NOX-
complexes, and mitochondria169,170. Errant ROS production is an early and pathogenic event 
in autoimmune neuroinflammation and is counteracted by redox mechanisms, e.g., NRF2 
mediated expression of antioxidants13,170-172. Moreover, catalase treatment reduces ROS and 
stabilizing the mitochondria, protects the axons, and ameliorates EAE173-176. Extracellular 
ROS is damaging myelin and axons and acts on the BBB to increase permeability177,178.  
Abrogated ROS production through NAPDH inhibition reduced infiltration of peripheral 
immune cells and ameliorated EAE177,178. In contrast, intracellular ROS production from 
CNS macrophages is induced by phagocytosis, and phagocytic clearance of myelin is 
suggested to demand ROS179,180. The effects of oxidative stress are, however, complex, and 
the MS drug dimethyl fumarate is shown to, besides its NRF2 activating abilities, also to 
increase peripheral oxidative stress in an immunomodulatory effect181 .   
 Re-myelination is regulated by myelin debris-clearance but also by cytokines secreted 
by glial cells and immune cells. The differentiation of OPCs and thus re-myelination is 
inhibited by TNF, IL-17, and IFN-γ found in MS lesions and produced by microglia, 
although they are not considered the primary source182-184. Macrophage NLPR3 
inflammasomes are found abundant in lesions of RRMS and primary progressive MS where 
IL-1β is a candidate biomarker for poor prognosis and possibly a treatment target185. In 
EAE, IL-1β has an ambiguous role, damaging through recruiting and polarizing T-helper 
cell phenotypes driving neuroinflammation. However, IL-1β also attracts and stimulates 
differentiation of OPCs and thus exhibits a positive impact on re-myelination186-189.  This is 
partly mediated through the induction of microglial secretion of LIF and IGF-1 acting on 
OPCs188,189. However, this is a complex issue, and IL-1β is also shown to delay re-
myelination in the Cuprizone de-myelination model185.  
Microglia are found early in MS lesions and participate in the recruitment and 
polarization of pathogenic peripheral immune cells by being a cytokine-source of, e.g., 
CXCL13 recruiting B-cells to the CNS, IL-1β and IL-23 polarizing pathogenic T-cells and 
allowing for monocytes to enter the CNS17,23,24,186. All with a crucial impact on EAE and 
correlating to MS disease14,16,17,19,24,190. The TAK1-NfKB axis regulates microglial cytokine 
expression that is a prerequisite for immune cell infiltration and de-myelination in 
developing EAE104. These events are at the crossroads of the “inside-out” vs. “outside-in” 
theories, where the latter represent the established idea that the event initiating a relapse is 
peripheral immune cells evading tolerance and entering the CNS191. The alternative “inside-
out” theory claims that myelin damage is the initial event followed by microglial activation 
and recruitment of peripheral immune cells, accelerating the damage192. Support for this 
comes from animal studies with induced oligodendrocyte or myelin damage leading to 







1.6 Ageing microglia   
The Ageing of an individual is not a uniform process in all its organs and cells. Microglia 
are cells with low mitotic activity, which keep the telomeric length but, on the other hand, 
opt out on the possibility of a fresh start as the cells accumulate misfolded proteins and 
leaky mitochondria194. Age is associated with an altered immune system, dysfunctional 
myeloid cells, neurodegeneration, and for MS patients associates with a switch to 
progression194-196. The core homeostatic microglial phenotype of adult mice in healthy 
conditions is also well represented in aged mice and humans, and the transcriptomes 
overlap between the species97,197,198. However, in both mice and humans, advanced age is 
associated with alterations in microglial subpopulations where transcriptomes indicate 
reduced signaling of the TGF-β pathway and increased expression of genes involved in 
vesicle biogenesis and phagocytosis, including APOE197,198. Despite this, functional 
microglial phagocytosis of protein aggregates and myelin debris decline with age while the 
lysosomal burden increases indicating either a dysfunctional degradation or higher 
degradational demand199-201.  The aged microglia accumulate leaky ROS-producing 
mitochondria and display NLRP3 inflammasome instability, both pathogenic in progressive 
MS and neurodegeration185,202,203. The age-associated changes in lysosomal degradation and 
ROS production associate with a so-called Lipofuscin accumulation of highly oxidized 
protein aggregates that in microglia cause further defects in metabolism, inflammatory 
polarization, altered morphology, and reduced survival77,200,204,205. Of note, these 
phenotypical changes and the microglial senescence could be derived from an age-
associated autophagy impairment, which is discussed in depth later.      
 As a cure for an age-associated decline in microglial function, an aged microglia 
replacement is proposed. In experimental models, the repopulating microglia had reduced 
cellular and tissue ageing features, including a lowered load of lipids and lysosomes and 
reduced Apoe expression77,206-208. The re-established microglia is further shown to 
differentiate accordingly to CNS-region defined cues208,209. The clinical impact from a true 
microglia replenishment of the myeloid CNS niche in EAE and MS remains to be 
evaluated.  
 
1.7 Infiltrating and border-associated-myeloid cells   
Microglia are the only CNS parenchymal myeloid cells in homeostatic conditions, but 
macrophages of other origins populate the CNS interfaces106. These populations, 
collectively referred to as BAMs or CAMs (Border or CNS Associated Macrophages, 
respectively; hereafter referred to as BAMs), reside in the perivascular space, the choroid 
plexus, and in the meninges. By fate-mapping, these cells are suggested to derive from an 
embryonic CD206+ population giving rise to BAM, while the CD206- is the origin of the 
TGF-β dependent microglia population210. Similar to microglia, BAMs rely on the 
transcription factors PU.1 and IRF8. These cells are self-renewing in homeostatic 
conditions, while depletion through CSF1R-blocking resulted in persistent contamination 
with bone marrow-derived myeloid cells210,211.       
 The BAM populations all have transcriptomes disparate from microglia except a 
small subset of macrophages residing in the choroid plexus210,211. This population shares the 
transcriptional signature with TREM2 derived DAM, suggesting the existence of a non-
parenchymal microglia-like cell, possibly the cell known as “Kolmer’s epiplexus cell” 
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described first in 1921211,212. As with other DAM´s, these cells have enriched expression of 
genes involved in phagocytosis and lipid metabolism, including Clec7a and Apoe, although 
in homeostatic conditions211. The BAMs are all targeted in the CX3CR1 inducible CRE 
model, but compared to microglia, they constitute tiny populations with no solid evidence 
of impact on MS and EAE, although they respond to experimental neuroinflammation by 
altered expression patterns106,213.  However, the meninges are considered a niche for 
lymphoid cells in progressive MS, and the choroid plexus is suggested to be a route of entry 
of T-cells in MS, implying these populations to influence a disease pathology not fully 
covered by animal models214,215.         
The inflamed CNS tissue in MS and EAE is infiltrated by classical and nonclassical 
monocytes differentiating into monocyte-derived dendritic cells and macrophages. 
Monocyte-derived DCs have an EAE-specific signature with, e.g., elevated expression of 
Clec9a coding a receptor binding necrotic cells for processing and cross-presentation106,216. 
The monocyte-derived macrophages are distinguished from microglia by, e.g., surface 
marker CD49d or high expression of CD44, CD45, or F4/80 and are functionally less 
health-promoting phagocytes during EAE18,78,106,110,114,217. Although microglia have 
pathogenic potential, executive functions in T-cell activation, de-myelination, and axonal 
damage largely depend on CCR2+ and/or Ly6C+ infiltrating bone marrow-derived myeloid 
cells18,114,186,218-220. In EAE, these cells egress from bone-marrow and enter the CNS in a 
CCL-2 and GM-CSF dependent manner18,21,186,219-222.  The pluripotent cytokine GM-CSF is 
found abundantly in MS lesions and demanded in EAE induction, and overexpression 
causes spontaneous neuroinflammation with infiltration of inflammatory 
monocytes20,21,186,221,222. Of note, these infiltrating myeloid cells do not seem to contribute 
to the CNS parenchymal myeloid population once the autoinflammatory EAE relapse is 
ceased220. The “M1” and “M2” macrophage nomenclature has not survived the complexity 
added by methodological advances but assigned “M2” bone marrow-derived macrophages 
such as CD206+ ARG1+ IGF1+ cells are associated to re-myelination, and transfer of TGF-
β stimulated macrophages ameliorates EAE119,223.     
Genes involved in antigen presentation, including the pivotal risk allele HLA 
DRB1*1501, are the strongest risk factors for MS where T-cells activated by APCs are 
pathognomonic3.  Microglia are known to be weak in APC functions in stimulating and 
polarizing T-cells, a function rather executed in the CNS in MS and EAE by monocyte-
derived DCs and macrophages106,224-227. Before entering the CNS, T-cells are activated in 
lymphoid tissues and/or possibly by the BAMs or DCs in the choroid plexus214,226,228.  
We can conclude that the myeloid CNS landscape can be far more complex and 
adaptive than previous notions, with functions defining subpopulations and associations to 
pathology to be discovered.     
 
1.8 AUTOPHAGY  
1.8.1 Canonical autophagy   
Canonical (macro)-autophagy is by definition a katabolic process degrading errant or 
superfluous intracellular proteins or organelles in an endosomal-lysosomal route. This 
process uses a set of proteins, commonly prefixed ATG, with defined functions at the 
different autophagosome formation steps. While the energy state of a cell and its 
surrounding tissue is the foremost regulator of autophagy, many other intra- and extra-
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cellular stimuli, including CSF1R, TREM2, and C-type lectin receptor engagement, also 
regulate myeloid cell autophagy75,229-231. The launching step of autophagosome formation is 
the pre-initiation complex assembly, a process induced by AMPK kinase activity and 
regulated negatively by Akt by activating the mTOR-complex. These pathways are 
regulated downstream the CSF1R and TREM2 and induce autophagosome maturation in 
myeloid cells by activating ERK1/266,128,130,232,233.  TREM2 is also shown to inhibit aberrant 
mTOR-mediated autophagy in a model addressing this receptor as a risk factor for 
Alzheimer´s disease229.  The aged microglia is shown to depend on alterations in mTOR-
signaling in acquiring the age-associated phenotype both in human and animal models234. 
 In canonical autophagy, the ULK1/2 acts as a regulated and regulating node acting 
downstream by phosphorylating core-autophagy proteins, including activation of the 
BECLIN1/VPS34 nucleation complex leading to formation the phagophore membrane235. 
With the vesicle membrane in place, the cargo for degradation is loaded in either a selective 
or non-selective process. The phagophore maturation to a double-layer autophagosome 
requires ATG7 activation of the ATG5-ATG12 complex and a cysteine residue's lipidation 
on MAP1LC3 (commonly referred to as LC3-II when lipidated) exposed by the ATG4 
kinase. LC3 is moreover suggested to have an additional role in the selection of cargo236.  
The LC3-II coat the autophagosome and is used as the standard defining marker of 
autophagy.  A RAB GTPase and SNARE protein mediate the fusion with a lysosome that 
finalizes the degradation of the autophagosome's and its cargo237. By being the main route 
of degrading various cellular components, autophagy is instrumental in cellular plasticity 
and survival, emphasized by the findings that mice carrying Ulk1/2, Atg5, or Atg7 
constitutive gene deletions are neonatally lethal238.  
Autophagy is generally considered to promote survival and differentiation in immune 
cells, while inhibition is associated with proliferation, including malignant 
myeloproliferation239,240. As many of the immune system mediators regulate autophagy, 
autophagy also controls immune responses by regulating the density of immune receptors 
and providing peptides for antigen-presentation exemplified by a model where Atg5 
deficiency specifically in dendritic cells ameliorates EAE228,241,242.  Autophagy directly 
regulates inflammasome stability and secretion of IL-1 superfamily cytokines, where IL-1β 
is well known in MS and EAE. Further, impaired canonical autophagy is entailed to 
harmful inflammatory processes, including ER stress and defective clearance of 
mitochondria causing dysregulated ROS production and increased Lipofuscin load204,243-247. 
Lipofuscin associates with cellular senescence which impairs function and reduces 
microglial density in chronic MS lesions13,248.   
 
1.8.2 Non-canonical autophagy and phagocytosis  
Non-canonical autophagy is a loose definition of cellular vesicular formations using parts 
of the autophagy protein machinery.  This nomenclature includes activities not traditionally 
addressed as autophagy, such as microbe degradation in “Xenophagy” and ATG dependent 
secretion of cytokines. In a process referred to as autophagy- or LC3-associated 
phagocytosis, myeloid cells load dying cells, debris, or microbes into phagosomes labeled 
by LC3-II for degradation through the autophagosomal-lysosomal path249. This process is 
induced by binding to a selection of myeloid surface receptors, including CD11b, TLR4, 
and phosphatidylserine receptors, including Tim 3/4 and Fc gamma receptor - all myeloid 
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receptors implicated in neuroinflammation250. Further, the engagement of CLEC7A is 
known to induce LC3-associated phagocytosis during fungal infections251,252. Autophagy-
associated phagocytosis is orchestrated by the protein RUBICON that simultaneously 
inhibits canonical autophagy by restraining VPS34253. This process is not regulated by 
mTOR and independent of the pre-initiation complex containing ULK1/2 but relies on the 
enzymatic activity of ATG7 in lipidation of LC3249,253,254. With the autophagy-defining 
lipoprotein embedded in the phagosome membrane, the lysosome fusion is facilitated, and 
phagocytosed content degraded249,253,254. In addition to LC3-II, degradation of this single-
layer auto-phagosome require ROS production from the NOX2 complex228,253. Moreover, 
halted degradation of these vesicles also influences clearance capacity by impeding 
retromer trafficking of scavenger and regulatory receptors, e.g., CD36 and TREM2134,255,256. 
 Impairment of the macrophage autophagy-associated phagocytosis is shown to 
aggravate inflammation and autoimmunity in an antibody mediated lupus-like disease and 
in models of autism, Alzheimer´s, and Parkinson´s disease with phenotypes derived from 
microglia deficiency in Atg5 or Atg7255,257-259. In these models, pathology associates both 
with errant tissue clearance of proteins and debris and with other functional alterations of 
the targeted microglia and macrophages, e.g. cytokine secretion253,255,257,260.   
 
1.8.3 Autophagy in the pathology MS and other human diseases                          
Genetic alterations and mutations causing dysregulated or functional impairment of 
autophagy are found in several human pathologies ranging from asthma to malignancies. 
Among these diseases, we find several neurodegenerative conditions such as ALS, 
Parkinson´s, and Alzheimer´s disease, where many risk genes associated with impaired 
degradation of mitochondria and errant ROS production261.  The accumulation of neuronal 
protein aggregates in neurodegenerative diseases such as Alzheimer´s, ALS, and 
Parkinson´s is suggested to be a result of dysfunctional autophagy-associated clearance262-
264. In Crohn´s inflammatory bowel disease, an ATG16L1 risk allele associates with 
increased mucosal inflammation261,265. This autoimmune disease entails an increased risk 
for developing MS and shows overlapping pathology to the one seen in the de-myelinated 
CNS255,257. Further, an impairment specifically in autophagy-associated phagocytosis is 
suggested in SLE pathology where an ATG5 allele increases risk supposedly through errant 
clearance and processing in phagocytosis of dying cells257,266.      
 In MS ATG4D, involved in LC3 labeling of autophagosomes in all forms of mammal 
autophagy, is detected as a risk gene for susceptibility7. Also, phagosome formation and 
maturation are detected as regulated pathways and RAB5, a GTPase important in 
phagosome maturation in, e.g., LC3 associated phagocytosis, have a highly significant risk-
allele for MS incidence7,253,255. Autophagy regulatory mTOR, AMPK, Akt, and ERK 
pathways are also detected in pathway analysis of MS risk-genes7.  Moreover, CLEC16A 
risk alleles in MS susceptibility associate mechanistically to MHC class II vesicular 
compartment maturation in a process suggested being autophagy dependent261,267-270. 
Finally, histopathological examination of microglia in MS lesions shows the increased 
density of autophagosomes and NOX2 activity, possibly linked to autophagy-associated 





             Autophagy 
 
1.8.4 Autophagy as a pharmaceutical target  
Autophagy is a major house-keeping pathway in most mammal cells, and pharmaceutical 
regulation is applicable both in, e.g., stimulated degradation of hazardous proteins, 
inhibiting tumor cell survival processes, and modulating the immune response, including 
IL-1β and ROS secretion. However, targeting of an essential function such as autophagy 
could potentially increase the incidence of adverse effects271.  The well-known autophagy-
inducer rapamycin reverses the mTOR suppression on autophagy and acts as an immune 
suppressant preventing allograft rejection. Rapamycin also ameliorates EAE partly through 
ERK1/2 activation and is recently shown to alter the age-associated microglial 
phenotype272,273.   Spermidine, found in, e.g., cheese, grains, and peppers, induces 
autophagy through downstream deacetylation of several ATGs and has been shown to 
increase lifespan in flies, worms, mice, and possibly humans mimicking benefits of calorie 
restriction274,275. In the MS-model EAE, spermidine alleviates clinical symptoms and 
pathology by polarizing monocytes to ARG1+ macrophages with reduced IL-1β 
secretion276,277.    
Another autophagy regulation goes through the activation of TFEB, a transcription 
factor stimulating autophagosome and lysosome component formation providing substrates 
for both canonical and non-canonical pathways shown protective in neurodegeneration and 
atherosclerosis through microglia and macrophage functions278-281. In these studies, TFEB 
activation is obtained upon treatment with trehalose, a sugar-molecules naturally occurring 
in, e.g., shellfish and mushrooms279,282. Trehalose is shown to induce autophagy through 
blocking surface glucose transport receptors on hepatocytes but how this associate with 
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TFEB and its relevance in myeloid cells remains to be explored283. Like spermidine, 
trehalose is not only suggested to have therapeutic potential for specific pathologies but 
also to act in general for CNS health and long life274,282,284. Importantly, trehalose 
metabolism is found associated with MS through a risk allele of the gene coding for the 
trehalose degrading enzyme trehalase7,285.  
The genetic MS-associations indeed put the autophagy pathway and potential 
influence of environmental factors in the form of trehalose in an excellent position for 
further work, perhaps also therapeutically.   
            
2 METHODOLOGICAL CONSIDERATIONS 
2.1 Mouse Cre-Lox models  
All experiments in Paper I, II, III were conducted using C57BL/6 mice. Gene ablation was 
accomplished using mice with cell-specific expression of the CRE-enzyme excising 
targeted genes flanked by lox(P) sites, referred to as Flox/Fl/fl. In homeostatic conditions, 
Cre expressed under the Lyz2 promoter targets primarily bone marrow-derived myeloid 
cells, and surprisingly also neurons286. Microglial Lyz2 expression and Cre-derived deletion 
are increased during inflammation106. Tamoxifen-induced Cx3cr1CreERT2 (hereafter referred 
to as Cx3cr1CreER) model has a high recombination frequency in the microglial population 
but is only specific when bone marrow-derived populations are replaced from the 
periphery, which is not necessarily the case for BAMs210,287,288. Considering this and the 
possible impact on phenotype from Tamoxifen itself, experiments were conducted at least 4 
weeks after the last Tamoxifen treatment. In this strain, CX3CR1CRE is fused with a yellow 
fluorescent reporter (eYFP) reporter.   
 
       Microglial targeting in the Cx3cr1CreER model 
 
2.2 Diphtheria-toxin mediated depletion of microglia 
Paper III is an application of thoroughly explored possibilities of depleting the microglial 
population78. The most successful depletion was accomplished by Cx3cr1CreER mediated 
deletion of a stop cassette in Rosa26DTA mice, leading to cell-specific diphtheria toxin 
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expression, which induces apoptosis and depletion of  >99% of CNS myeloid cells. This 
could be maintained by Tamoxifen treatment-induced Cre expression. By transferring 
Lyz2CreTgfbr2fl/fl or Cx3cr1CreER Tgfbr2fl/fl to irradiated Cx3cr1CreERR26DTA recipient mice 
creating a chimera, a depletion was combined with a specific gene deletion in the monocyte 
and BMDM populations.  
 
2.3 The EAE model   
The EAE model employed in these studies was induced by active immunization with mouse 
recombinant MOG 1-125aa protein. The de-myelination occurs primarily in the spinal cord 
upon infiltration of peripheral immune cells and activation of microglia. This pathology 
includes inflammation, de-myelination and axonal damage/neuronal death. The induction of 
active EAE in C57BL/6 requires Freund´s complete adjuvant containing Mycobacterium 
tuberculosis which leads to pattern recognition receptor activation and amplification of the 
immune response. Immunization is accompanied by intraperitoneal injections of Bordetella 
pertussis toxin, which induces myeloid cell IL-1β secretion and possibly regulate BBB 
permeability19,289-291. In Paper I and III, mice of advanced age were used. Aged mice are 
known to have heterogeneous phenotypes and develop aggravated EAE upon MOG 
immunization. 
 
2.4 Microglial phenotyping in vivo and in vitro  
In our studies, dynamics of microglial phenotypes were evaluated by transcriptional 
analysis, ELISA cytokine quantification, flow cytometry, functional assays, and 
immunocytochemistry.  Disease processes were examined and visualized by 
immunohistochemistry of CNS with microglia and macrophages at the site of pathology. 
Tools for studying specifically microglia and exclude bone marrow-derived macrophages 
are still developing. While microglia in flow cytometry can be defined as CD45Intermediate 
CD11b+ Ly6G- under homeostasis, in the inflamed CNS no definite microglial marker for 
immunohistochemistry analysis is available. Healthy conditions offer, however, several 
microglia-specific markers such as TMEM119, SALL1 and P2RY12. Of note, the 
microglia signature is rapidly lost when cells are extracted from the CNS and cultured in 
vitro as they acquire an activated age-associated phenotype292. Time in culture and in vitro 
experiments were due to this kept to a minimum.   
 
2.5 Autophagy monitoring and phagocytosis assays  
In Paper I and II, autophagy was targeted by deletion of core autophagy genes Ulk1 and 
Atg7. Ulk1 has high homology with Ulk2 also expressed in microglia, but the up-, and-
down-stream regulation differs between the paralogs60,61,293. The consequence on 
autophagocytosis from these deletions was assessed as, e.g., IL-1β secretion, mitochondrial 
load, and LC3-II+ autophagosome densities after starvation phagocytic intake. Myelin-
containing phagosomes targeted for degradation through the autophagy-lysosomal pathway 
were detected by membrane-bound LC3-II in an analysis where a mild permeabilization 
protocol allowed for unbound LC3-I to diffuse from the cytosol. In Paper I, we designed 
an experiment for flow cytometry to analyze the intracellular localization of phagocytosed 
content. Myelin or apoptotic cells were conjugated to one dye fluorescent in low pH 
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(lysosomes) and one emitting in a pH-independent manner (vesicles or cytosol). These 
experiments and most phagocytosis quantification detect uptake as intracellular content 
such as myelin or bacterial compounds, which is misleading regarding phagocytic clearance 
if the degradation of phagosomes is errant. To address this, we measured the capacity to 
clear myelin debris by exposing microglia and bone marrow-derived macrophages to 
fluorescent myelin, followed by quantification of the remaining myelin in the culture 
medium.  
 
2.6 Analysis of RNA sequencing data  
In Paper I and III, comprehensive expression analyses of RNA sequencing data were used 
to phenotype microglia. Differentially expressed genes (DEGs) were analyzed and 
visualized by detection of regulated pathways and pathologies in Ingenuity pathway (IPA) 
analysis, REViGO, and Over-representation analysis (ORA).  We further employed a Gene 
Set Enrichment Analysis (GSEA) to investigate differences in expression between strains 
regarding predefined expression signatures. This was employed to compare our sequencing 
data to DAM-subpopulation signatures defined by single-cell RNA sequencing of microglia 
in, e.g., MS and Alzheimer's disease models. However, our experiments aimed not to 
identify new subpopulations that arise in the models deficient in targeted genes but rather to 
contextualize the general shifts in microglial phenotypes. 
3. ETHICAL CONSIDERATIONS 
For obvious reasons, CNS tissue from humans is not easy to access, and animal 
experiments have been instrumental in finding cues in treating and understanding 
neurological disease and treatment targets. Experimental animal research entails a 
responsibility to ensure quality and careful planning to reduce suffering. I have, through the 
Ph.D. education kept the use of animals to the minimum without hampering statistical 
significance. During the later parts of my education, I refined my technical skills and could 
use the same animal for several experimental analyses. To replace in vivo and ex vivo 
experiments was not possible due to the tissue-dependent nature of targeted microglial 
cells. All experiments have been conducted according to the ethical permits. 
4. AIMS 
Paper I  
To characterize how impaired autophagy by gene ablation or age-associated decline 
influence cellular phenotype and clinical EAE. We further aimed to explore if this pathway 
could be targeted pharmacologically to ameliorate disease.   
 
Paper II  
To investigate if microglia depend on autophagy in maintaining a CNS protective 
population during ageing.  
 
Paper III  
To study if peripheral cells depend on TGF-β in the process of integrating to the microglial 




5.1. Paper I  
Previous studies by our group associated reduced Atg7 expression in immune cells to 
aggravated EAE in an unbiased approach in rat-strain crosses294. We induced Atg7 
deficiency in T-cells under the Lck promoter and myeloid cells under the Lyz2 promoter in 
a mouse Cre-Lox system. The deletion in T-cells had minor effects on CD8+/CD4+ T-cell 
proportions in lymph nodes and did not affect clinical EAE. The Lyz2-CRE driven Atg7 
deletion was associated with a loss of recovery from EAE. Since Lyz2 is expressed in many 
of the myeloid cells involved in EAE, we quantified Atg7 expression in different subsets 
and found Atg7 highly expressed and regulated in the CNS resident myeloid cell microglia. 
We also found deletion of floxed Atg7 in microglia under the Lyz2 promoter to be elevated 
during inflammation. To further explore this, we generated a model with microglia-specific 
deletion of floxed Atg7 using the Cx3cr1CreERT2/+ (hereafter referred to as 
Atg7fl/flCx3cr1CreER), which have the benefit of an inducible deletion. This is important 
since autophagy has many key functions in the development, differentiation, and survival of 
the cell, tissue, and individual.         
 The clinical EAE in the Atg7fl/flCx3cr1CreER reproduced the chronic course seen in the 
Lyz2CRE model, supporting a notion of a microglia-derived phenotype in both strains. In MS 
and EAE, phagocytic clearance of dead cells and myelin debris is suggested to be a 
microglial duty, and microglia lacking Atg7 had accumulations of intracellular myelin. 
Compared to Wt, we found the myelin-containing phagosomes in autophagy-impaired 
microglia to have reduced LC3-II labeling and impaired loading into low-pH lysosomes. 
This concludes a dysfunctional phagocytic degradation through LC3-/autophagy- 
associated phagocytosis, a process previously known in macrophage context in models of 
SLE and Alzheimer´s disease 255,257. This process was discriminated from canonical 
autophagy by employing deletion of Ulk1, an autophagy protein not demanded in 
autophagy-associated phagocytosis. Further, the expression of the master regulator of 
autophagy-associated phagocytosis Rubicon was found upregulated early during EAE, 
which supported the importance of this process. In a myelin clearance assay, we aimed to 
explore if the impaired degradation affected the uptake and hence clearance of tissue debris. 
The Atg7-deficient microglia had a rapidly exhausted capacity of myelin clearance, and 
after exposure to myelin debris in vivo and in vitro, they accumulate not only the content 
but also myelin scavenger receptors MSR1 (SCARA1, CD204, SR-A) and CD36. We 
further validated this path by detecting MSR1 blockade to inhibit myelin uptake and 
blocked lysosomal fusion to reduce receptor-recirculation.    
Analyses of EAE CNS detected an increased intracellular myelin load in microglia 
lacking Atg7 accompanied by an increased load of tissue myelin debris and consequential 
reduction in OPC differentiation to myelinating cells. During EAE, the Atg7fl/flCx3cr1CreER 
mice had increased immune cell infiltration to the CNS, including bone marrow-derived 
macrophages. However, these cells could not compensate for the reduced phagocytic 
capacity of microglia, supporting the idea of microglia as the primary myelin phagocyte 
during CNS inflammation. RNA sequencing of microglia sampled during EAE associated a 
DAM signature to the Atg7 deficiency.  Accordingly, we found upstream DAM regulators 
TREM2 and Apoe highly expressed in Atg7fl/flCx3cr1CreER microglia during EAE. We could 
also define and validate true subpopulations based on CLEC7A, one of the DAM signature 
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genes. The CLEC7AHigh population was increased in counts in the CNS of 
Atg7fl/flCx3cr1CreER mice and possessed this model's highlighted impairments, including 
accumulated intracellular MSR1. Pathway analysis of microglia during EAE revealed 
activated inflammatory pathways detected as enriched IFNy and GM-CSF signaling in Atg7 
deficient microglia at day 21 p.i. The later day 35 p.i. timepoint showed regulation of, e.g., 
metabolism and oxidative stress pathways associated with progressive MS3,5,115.  
 Autophagy is a process known to decline with age, which also is a strong risk factor 
for progressive MS. As discussed above, several genes implicated in autophagy and 
phagocytosis have allele variants associating with MS risk7. By treating aged mice with 
trehalose, a sugar molecule found in, e.g., plants, fungi, and shellfish, we could reverse the 
aggravated EAE associated with age in a microglia-dependent fashion. Trehalose induced 
TFEB nuclear transfer and thus transcriptional activity, increasing the biogenesis of 
autophagosomes and lysosomes. Our experiments found a specific effect on autophagy-
associated phagocytosis as the effect was not abrogated by ULK1 deficiency.   
  This study shows how microglia regulates EAE recovery through phagocytosis of 
myelin and associated phenotypic alterations. We also showed how age-associated 
impairments in this process could be reversed by a dietary sugar compound potentially 
affecting a pathway untargeted by available medications and possibly of certain importance 
in age-associated progressive MS.          
          Graphical abstract for Paper I 
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5.2 Paper II  
As age entails altered canonical-autophagy and microglial phenotypes, we sought to 
examine this in the context of CSF1R signaling and neuroinflammation4,234,295,296. In the 
aged CNS (>20 months), we found microglia to have a reduced proliferation tied to an 
increased cell survival indicating a slower turnover compared to adults (<5 months). While 
CSF1R, the main receptor for microglial survival and proliferation, had reduced surface 
density on aged microglia, the corresponding ligands CSF-1 and IL-34 had elevated 
expression in the aged CNS. By analyzing known phosphorylation-sites downstream of 
CSF1R engagement, we found aged microglia to have increased activating phosphorylation 
of ERK1/2, AMPK, and a reduced activating Akt phosphorylation. Consequently, aged 
microglia were significantly more sensitive to ERK1/2 inhibition. AMPK induces 
canonical-autophagy through the mTOR and pre-initiation autophagosome complex, 
including ULK1 activation, an effect inhibited by activated Akt.  ULK1 activation is known 
to activate ERK1/2 and to be important in cellular survival243,297. Knowing this, we 
generated mice with a specific microglial deletion of floxed Ulk1 upon Tamoxifen induced 
CRE-expression under the CX3CR1 promoter (hereafter referred to as Ulk1fl/flCx3cr1CreER). 
In adult mice, the microglia population kinetics was not affected upon this deletion, but 
after about 2 years, the population was significantly reduced by about 40%. Importantly,  
this reduction was not compensated by infiltration of other macrophages.  
We traced the diminished microglia specifically to a loss of the highly activated 
ERK1/2 population and that ULK1 deficient microglia suffered from increased ER-stress 
associated with apoptosis. The loss was most prominent in the cerebral cortex. This chain 
of autophagy impairment and apoptosis has previously been described in other cells243. 
ERK1/2 is suggested to be an upstream regulator of DAM microglia characterized by a 
reduced CSF1R, increased CSF-1, and further by subpopulation markers such as the MHC 
class II, TREM2 and CD11C (ITGAX) 272,298. In the autophagy-dependent microglia 
population with highly activated ERK1/2, these markers were found at a higher density, 
supporting an activated DAM subpopulation attribute.      
 In order to expand this Autophagy Dependent Age-acquired Microglia, referred to as 
“ADAM”, we treated aged Wt and Ulk1fl/flCx3cr1CreER aged mice with intracisternal CSF-1 
and IL-34 injections. CSF-1 treatment evoked in both strains a large increase of the 
microglia less autophagy-dependent and reduced activation of ERK1/2. Conversely, the IL-
34 treatment caused a substantial expansion of the ADAM population. This IL-34 induced 
expansion was specifically canceled in the Ulk1 deficient mice revealing an aged microglial 
IL-34/CSF1R/ULK1 axis. Notably, we did not see a significant infiltration of peripheral 
immune cells in any strain or treatment condition.      
 The absent ADAM and the reduced microglia population without peripheral 
infiltration revealed a unique opportunity to study the influence of microglia on disease 
pathology in the MS model EAE, which is known to aggravate with age. We found the 
EAE in aged mice deficient in ADAM to associate with high mortality not rescued by IL-34 
or CSF-1 treatment even though the latter has similar total microglial counts as aged Wt 
mice. By quantifying neurons and glial cells by number and apoptosis markers, we found 
the loss of the ADAM population to associate with a significant reduction of OPC, OLs, 
and neurons as well as microglia themselves during EAE. Upon IL-34 induced expansion 
of the ADAM in aged Wt mice, we detected a significant reduction in clinical scores and 
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increased survival of microglia and CNS cells during EAE. We could also reproduce a 
neuroprotective effect from IL-34 treated microglia in vitro and detected several 
neurotrophic factors increased in expression in microglia upon this specific stimulation.  
 This study discovered and characterized a CNS protective microglial population 
acquired with age defined by a demand for autophagy protein ULK1 and activated ERK1/2. 
The absence of this population is associated with aggravated disease phenotypes regardless 
of total microglial density. Importantly, this population expanded specifically upon IL-34 
treatment, a finding to consider when targeting  the CSF1R in modeling and treatment of 
microglia-associated pathologies.  
 
 
          Graphical abstract for Paper II 
 
5.3 Paper III  
TGF-β is known to be crucial in establishing a mature microglial homeostatic 
phenotype98,99. The microglial niche in the CNS parenchyma is, under inflammatory 
challenges and depletion, populated partly by infiltrating monocytes differentiating into 
bone marrow-derived macrophages. Our group's previous findings show how depletion is 
followed by competitive repopulation by microglial cells and monocytes and how these 
cells adopt shared phenotypes shaped by the tissue surrounding and an intrinsic signature 
defined by origin78. We found the deletion of the TGF-β receptor in Lyz2 expressing 
monocytes to associate to reduced integration of bone marrow-derived cells into the CNS 
parenchyma after microglial depletion. Thus indicating a demand for this cytokine 
signaling in the migration process or survival and expansion in the target tissue.  
 In order to silence TGF-β signaling in the repopulated CNS myeloid cells, we utilized 
the finding of an upregulated Cx3Cr1 expression in the infiltrating bone-marrow derived 
cells. This allowed us to employ the inducible deletion of floxed Tgfbrfl/fl upon Tamoxifen 
induced Cx3cr1CreER post infiltration to the CNS of bone-marrow-chimeric mice. The lack 
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of TGFΒR2 in this population altered the transcriptome with upregulation of genes 
associated with antigen-presentation, inflammation and phagocytosis. About 12 days after 
gene deletion, the mice developed a progressive motor impairment and died around 10-25 
days later. Immunohistochemistry revealed de-myelination and axonal dysfunction in 
association to myelin-laden giant macrophages in the dorsal spinal cord, causing fore- and 
hind-limb palsy and late-stage disease also affecting the brain. Without depletion, TGBFR2 
deletion specifically in microglia caused similar pathology and symptoms but with later 
disease-onset compared with the monocyte repopulation model.      
 In conclusion, we show how bone marrow cells demanded TGF-β signaling to 
establish a CNS parenchymal myeloid cell and how this population, once settled, requires 
TGF-β to inhibit a pathogenic macrophage process. This is in line with the need for TGF-β 
for microglia during developmental establishment and maintenance of a homeostatic 
phenotype and could be employed in microglial/macrophage replacement therapy and to 
polarize these populations. 
 
 








6. DISCUSSION AND FUTURE PERSPECTIVES  
This thesis supports the notion of microglia as guardians of the CNS and how malfunctions 
of these cells cause pathology due to lack of health-promoting capacities. The microglial 
cell has been defined by localization and morphology for a century, but we still struggle to 
determine unique microglial signatures and features to distinguish them from bone marrow-
derived macrophages. This and the obstacles CNS offer regarding tissue sampling in vivo 
are factors delaying the understanding of microglia in disease and a health-promoting 
context. 
 
Microglia-specific gene targeting is still a struggle  
The Cx3Cr1CreER model targeting microglia is valuable but not completely decisive in its 
specificity and is likely to be contaminated by BAM.  As an alternative, a Hexb promotor 
has been presented as microglia specific and stable in homeostatic and inflammatory 
conditions299. Another suggestion is to combine a myeloid promoter with a CNS specific, 
e.g., Cx3Cr1 and Sall1 with split Cre-fragments287.  However, we should acknowledge the 
pitfalls of all models in excluding microglial subpopulations and/or including other 
immune- or CNS-cells. 
 
Microglial depletion and replacement  
Microglial replacement therapies upon, e.g., CSF1R inhibition are proposed to ameliorate 
degenerative and inflammatory neuropathology. Due to the accumulation of leaky 
mitochondria, impaired autophagy, accumulated mutations, and lipid inclusions, 
replenished microglia could substantially impact age-associated CNS disease. Our group's 
previous findings and the results presented in Paper III show that bone marrow-derived 
cells can contribute to a re-established myeloid CNS population following depletion and 
how TGF-β signaling is demanded and beneficial in maintaining a health-promoting cell in 
this microglia niche. This can be employed in a desirable treatment regime in polarizing a 
population that, once established, does not need further pharmaceutical support. Paper III 
further emphasizes previous findings that tell us that microglial origin matters and possibly 
that replacement therapies should actively inhibit colonization by myeloid cells of bone 
marrow origin. Given the troubles of depletion models regarding lack of specificity and 
undesired inflammation caused by cell death and/or toxins, our strategies of specific 
targeting of repopulating cells presented in Paper II and III is valuable for future work. In 
addition to the discovery of myeloid-derived pathogenicity shackled by TGF-β.   
Up to date, there is no evidence of bone marrow-derived myeloid contribution to the 
CNS parenchymal myeloid cell population during homeostasis or even after the acute 
inflammatory challenge. Yet, we need to study this in a broader context investigating 
influence from ageing, chronic inflammation, and cytostatic or immune-modulatory 
treatments since a possible contribution of a bone marrow-derived cell likely affect 
pathology.  
 
Disease-associated microglia – Loss of a health-promoting phenotype or intrinsic 
pathogenicity?  
Microglia described as “activated”, “amoeboid,” and recently “DAM” have been addressed 
as pathogenic based on its context of inflammatory and neurodegenerative disease, and 
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largely by parameters adopted from phenotyping of bone marrow-derived myeloid cells, 
e.g., molecules associated to antigen-presentation. A likely more relevant idea is now 
emerging that activated microglia found in the inflammatory CNS lesions have designated 
functions in restoring a healthy CNS, where phagocytosis is a prominent feature shown in 
Paper I and by others4,101,106,134,155,300. This implies the defects in myelin processing and 
scavenger receptor recirculation associated with ATG7 deficiency shown in Paper I to be 
assigned a dysfunctional DAM rather than this population to have an intrinsic pathogenic 
phenotype. It is also possible that the impairment of the key phagocytic function causes an 
accumulation of this microglial subpopulation, defined by, e.g., CLEC7A density, on the 
cost of other subpopulations with features important in the recovery from inflammation. 
However, the DAM phenotypes are, for the most part, defined by single-cell RNA 
sequencing analyses and still need to be validated as spatially or functionally distinct 
populations or as transient responsive differentiation stages. 
 
Autophagy-associated phagocytosis in MS and EAE   
The list of suggested diseases with myeloid cell autophagy-associated phagocytic 
dysfunction is growing, and this pathway cannot be viewed as something irregular. One 
question that remains unanswered is if this is only a degradation pathway, or if the cargo 
selection has specific regulatory functions, and if the cargo by vesicle specifics is destined 
towards certain functions, e.g., antigen presentation. Another issue is how activation of this 
RUBICON-directed pathway affects canonical-autophagy functions during long-term 
exposure to, e.g., myelin or apoptotic cells. The process of autophagy-associated 
phagocytosis is also largely understudied in human disease, and findings by us in Paper I 
and others need to be reproduced or supported by studies on the pathogenesis of the human 
disease. This is also called for by the autophagy-associated genes and pathways detected in 
MS susceptibility genetics.  
 
CSF-1 vs. IL-34 promoted microglial subpopulations in the aged CNS  
The aged CNS was further explored in Paper II where we found a microglial population 
with activated ERK1/2, a known upstream regulator or the DAM microglia phenotype, to 
be dependent on canonical autophagy. This population referred to as “ADAM” was found 
protective during EAE, and loss of this population in the aged mice deficient in microglial 
ULK1 associated with high mortality, immune cell infiltration, and CNS cell death. Recent 
publications have explored the regional developmental disparate effects of IL-34 and CSF-
1. We could expand the ADAM population specifically upon IL-34 treatment, which 
significantly reduced the signs of neuroinflammation compared to the CSF-1 treatment, 
which selectively expanded the autophagy-independent population with low ERK1/2 
activation. We should also highlight that even though CSF-1 is associated with DAM and 
act on other cells than microglia, this treatment did not aggravate EAE disease. The 
evidently increased density of activation markers in the IL-34 expanded ADAM population 
supports a microglial DAM-phenotype with protective capacity.  However, besides the IL-
34 induced expression of neurotrophic factors the executive functions derived specifically 
from the two CSF1R ligands and to which degree they are redundant remains to be shown. 
 In conclusion, Paper II highlights the demand for canonical autophagy to maintain a 
microglial population with unique neuroprotective features during EAE. We can also view 
this model as a partial microglial depletion model, where the depletion in comparison to 
 
24 
other models is less effective but silent and not compensated by bone marrow-derived 
myeloid cells. How this affects the ageing CNS could be explored further in homeostatic 
conditions or other disease models, including exploring the suggested IL-34 specific 
effects. 
The findings in Paper II revealing the age-acquired microglial subpopulation with 
higher demand for canonical-autophagy, suggesting this pathway rather more activated than 
declined with age. This is somewhat supported by an altered microglial phenotype 
downstream mTOR signaling recently reported234. However, in Paper I, we find an 
increased expression of DAM-associated genes in microglia deficient in both canonical and 
non-canonical autophagy shared partly with aged microglia. This further supports that the 
autophagy-dependent phenotype or subpopulation is acquired during ageing. One could 
also speculate an increased canonical-autophagy to occupy the autophagy proteins in aged 
microglia and thereby reduce the capacity for non-canonical autophagy associated 
phagocytosis — a deficiency we targeted by trehalose treatment in Paper I. 
 
Induced autophagy as a potential therapeutic target in neuroinflammation  
Loss of EAE recovery in the C57BL/6 model should probably be addressed as a prolonged 
inflammatory relapse rather than a transition to the progressive phenotype seen in human 
MS. This does not exclude shared specific pathways such as microglial autophagy. It is also 
possible that the aggravated EAE associated with age suffers from the same pathology as 
the progressive human disease.  In contrast to models of neurodegeneration, studies in EAE 
addressing age is underutilized and likely informative.   
The phenotypes presented in Paper I and II add to an emerging concept of autophagy 
as regulatory and executive function in myeloid cells. While immune-modulatory 
treatments commonly dampen the immune surveillance at large, autophagy induction 
tentatively has beneficial effects in surveillance of tumor cells and microbes and 
simultaneously dampening an aberrant immune activation. In general, boosting an immune 
function is rare in comparison to restraining immunity as a treatment regime. If this is due 
to complications or is an underused path remains to be seen.  
The findings of trehalose ameliorating age-associated neuroinflammation in Paper I 
are promising and novel in targeting autophagy-associated phagocytosis. This could 
potentially be implemented as a dietary adjustment to reduce the risk of developing a 
disease or halt disease progression. However, deliberate trehalose supplementation should 
also be considered an option.  
In this thesis, I present findings and ideas of health-promoting pathways in cells of 
the CNS microglial niche showing cellular phenotypes and functional outcomes. 
Knowledge of these cells is rapidly expanding and holds answers and offers solutions 
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